Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19
Novel Phase 3 Trial Design to Evaluate Bemnifosbuvir as Monotherapy and Combination Antiviral Therapy for COVID-19 Trial to Focus on High-Risk Patients at Greatest Risk for Disease Progression ... | September 13, 2022
United States Jean Pierre Sommadossi Jonae Barnes Company Investor Relations Emergency Task Drug Administration
Source: marketscreener.com